Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
07 Apr 2021
Historique:
entrez: 8 4 2021
pubmed: 9 4 2021
medline: 15 5 2021
Statut: epublish

Résumé

We report a case of progressive light-chain amyloidosis (otherwise known as AL amyloidosis) with acquired factor X (aFX) deficiency with a complete haematological response and rapid normalisation of FX levels following daratumumab monotherapy. To our knowledge, this is the first case report documenting successful treatment with daratumumab of aFX deficiency secondary to AL amyloidosis. The patient responded well to this therapy, with excellent symptomatic and quality of life improvements as well as a reduction in bleeding manifestations. This case highlights the value in considering daratumumab treatment when AL amyloidosis is complicated by FX deficiency.

Identifiants

pubmed: 33827877
pii: 14/4/e240631
doi: 10.1136/bcr-2020-240631
pmc: PMC8030679
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Blood. 2020 Apr 30;135(18):1541-1547
pubmed: 31978210
Amyloid. 2019 Dec;26(4):255-256
pubmed: 31526149
Blood. 2001 Mar 15;97(6):1885-7
pubmed: 11238135
Blood. 2016 Jul 28;128(4):594-602
pubmed: 27257181
J Clin Oncol. 2020 Oct 1;38(28):3252-3260
pubmed: 32730181
Blood. 2017 Apr 27;129(17):2443-2454
pubmed: 28213380
Blood. 2014 May 1;123(18):2899-900
pubmed: 24786460
Blood. 2020 Apr 30;135(18):1517-1530
pubmed: 32107537
Blood. 2020 Apr 30;135(18):1531-1540
pubmed: 32108228
Arch Intern Med. 1983 Mar;143(3):597-9
pubmed: 6830397
J Gastrointest Surg. 2004 Mar-Apr;8(3):358-62
pubmed: 15019934
Br J Haematol. 2000 Aug;110(2):454-60
pubmed: 10971408
Leuk Lymphoma. 2019 Feb;60(2):295-301
pubmed: 30033840
Blood Coagul Fibrinolysis. 2016 Jan;27(1):101-8
pubmed: 26218969
Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):10-14
pubmed: 30879471
Am J Hematol. 2010 Mar;85(3):171-3
pubmed: 20052750
N Engl J Med. 1981 Apr 2;304(14):827-30
pubmed: 7207512

Auteurs

Ethan Mar (E)

Department of Haematology, Metro South Hospital and Health Service, Woolloongabba, Queensland, Australia ethanmar06@gmail.com.

Kerry Taylor (K)

Icon Cancer Care, Mater Medical Centre, Brisbane, Queensland, Australia.

Peter Mollee (P)

Department of Haematology, Metro South Hospital and Health Service, Woolloongabba, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH